Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes — Stella

Home/Healthy Volunteer/Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes

View on ClinicalTrials.gov

Recruiting

Back to Healthy Volunteer trials

Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Israel

Sheba Medical Center, Ramat Gan, Please Select

Key details

Phase

Early testing

Sponsor

Cohen Global, Ltd.

Enrollment target

~54 participants

Started

January 2025

Primary completion

February 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 70 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.